Johnson & Johnson (NYSE:JNJ) Shares Purchased by Transamerica Financial Advisors Inc.

Transamerica Financial Advisors Inc. increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 178.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,458 shares of the company's stock after purchasing an additional 6,708 shares during the quarter. Transamerica Financial Advisors Inc.'s holdings in Johnson & Johnson were worth $1,695,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. Innealta Capital LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth $27,000. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares during the last quarter. Activest Wealth Management purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $40,000. Finally, Morton Brown Family Wealth LLC increased its stake in shares of Johnson & Johnson by 400.0% in the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock valued at $41,000 after purchasing an additional 200 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.8 %

Shares of JNJ stock traded down $1.27 during trading on Tuesday, hitting $154.51. 5,680,722 shares of the stock traded hands, compared to its average volume of 7,069,779. The firm has a market capitalization of $372.00 billion, a P/E ratio of 22.36, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm's fifty day moving average price is $159.73 and its 200-day moving average price is $156.39. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.66 EPS. As a group, research analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson's payout ratio is 71.78%.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target for the company. Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $175.94.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company's stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.